KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $216.0 million.

  • Charles River Laboratories International's Other Accumulated Expenses rose 529.72% to $216.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.0 million, marking a year-over-year increase of 529.72%. This contributed to the annual value of $194.0 million for FY2024, which is 452.54% down from last year.
  • Latest data reveals that Charles River Laboratories International reported Other Accumulated Expenses of $216.0 million as of Q3 2025, which was up 529.72% from $207.2 million recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's Other Accumulated Expenses ranged from a high of $216.0 million in Q3 2025 and a low of $97.3 million during Q1 2021
  • Over the past 5 years, Charles River Laboratories International's median Other Accumulated Expenses value was $194.0 million (recorded in 2024), while the average stood at $182.3 million.
  • As far as peak fluctuations go, Charles River Laboratories International's Other Accumulated Expenses tumbled by 1062.52% in 2021, and later skyrocketed by 4847.2% in 2022.
  • Charles River Laboratories International's Other Accumulated Expenses (Quarter) stood at $140.4 million in 2021, then surged by 45.67% to $204.6 million in 2022, then dropped by 0.67% to $203.2 million in 2023, then decreased by 4.53% to $194.0 million in 2024, then rose by 11.31% to $216.0 million in 2025.
  • Its Other Accumulated Expenses stands at $216.0 million for Q3 2025, versus $207.2 million for Q2 2025 and $211.5 million for Q1 2025.